First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

QR Code

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Background The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pati...

Full description

Bibliographic Details
Main Authors:	Wu, Y-L, Zhou, C.., Liam, Chong-Kin, Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., How, Soon Hin, ., et al.
Format:	Article
Language:	English English
Published:	Oxford University Press on behalf of the European Society for Medical Oncology 2015
Subjects:	RC Internal medicine
Online Access:	http://irep.iium.edu.my/44211/ http://irep.iium.edu.my/44211/2/firstline_erlotinib.pdf http://irep.iium.edu.my/44211/6/44211_First-line%20erlotinib%20versus%20gemcitabine_SCOPUS.pdf

Similar Items

Aerosolized niosome formulation containing gemcitabine and cisplatin for lung cancer treatment: optimization, characterization and in vitro evaluation
by: Mohamad Saimi, Norfatin Izzatie, et al.
Published: (2021)

Epidermal growth factor receptor (EGFR) mutations are the main oncogenic driver mutation in adenocarcinoma in never-smokers - findings from the emlan study
by: Liam, Chong Kin, et al.
Published: (2012)

Formulation and optimization of nanoemulsion containing gemcitabine for lung cancer treatment
by: Wahgiman, Nadiatul Atiqah
Published: (2019)

Development of aerosolized niosome formulation containing gemcitabine and cisplatin for in-vitro cytotoxicity against MRC5 and A549 cell lines
by: Mohamad Saimi, Norfatin Izzatie
Published: (2020)

EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
by: Valle, Juan W., et al.
Published: (2015)

Epidermal Growth Factor Receptor Mutation in Newly Diagnosed Lung Adenocarcinoma
by: Chee, Shee Chai, et al.
Published: (2017)

Lung cancer in Malaysia
by: Rajadurai, Pathmanathan, et al.
Published: (2020)

Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic Malaysian patient population
by: Liam, Chong-Kin, et al.
Published: (2014)

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer
by: Petty, W., et al.
Published: (2011)

Identification of deregulation in protein expression level of erlotinib-resistant H1299 cell lines
by: Mat Daud, Syukriyah
Published: (2015)

Identification of deregulation in protein expression level of erlotinib-resistant A549 cell lines
by: Mohd Noh, Noor Khafizah
Published: (2015)

Characteristics of epidermal growth factor receptor (EGFR)-Mutated Non Small Cell Lung Carcinoma (NSCLC)-patients who developed resistance to first or second generation Egfrtyrosine Kinase Inhibitor (TKI) Therapy through T790M mutation / Vijayan Munusamy
by: Vijayan, Munusamy
Published: (2017)

Homing peptides (rgd/irgd) functionalized zeolitic imidazolate framework-8 for targeted delivery of gemcitabine to lung cancer cell
by: Mohd Abdul Kamal, Nurul Akmarina
Published: (2022)

Optimization of nanoemulsion containing gemcitabine and evaluation of its cytotoxicity towards human fetal lung fibroblast (MRC5) and human lung carcinoma (A549) cells
by: Wahgiman, Nadiatul Atiqah, et al.
Published: (2019)

A prospective study on epidermal growth factor receptor mutations in non-small cell lung cancer in Malaysian patients
by: Liam, C K, et al.
Published: (2012)

The contemporary growth regime has been ensured by the Australian state's mutations (at least until now)
by: Chester, Lynne
Published: (2008)

Molecular docking analysis on the designed benzimidazole derivatives as EGFR inhibitors: comparison between EGFR wild-type (EGFRWT) and T790M mutant
by: Nurul Awani Syazzira Jalil,, et al.
Published: (2023)

Development of an EGFR-targeted Drug Delivery System for Glioblastoma
by: Zhao, Zi-Ruo
Published: (2023)

Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia
by: Wander, P., et al.
Published: (2020)

Dynamics of ligand and nanobody binding at CXCR4/EGFR complexes
by: Comez, Dehan
Published: (2025)

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First-line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
by: Chee, Shee Chai
Published: (2017)

Detection of Isocitrate Dehydrogenase (IDH-1), Epidermal Growth Factor Receptor (EGFR), P53 and C-erbB2/HER2 mutation in glial tumour
by: Azman, Nusaibah, et al.
Published: (2022)

Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
by: Middleton, Gary, et al.
Published: (2017)

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
by: Middleton, Gary, et al.
Published: (2014)

The Chemo-Sensitisation Effect Of Curcumin Against Low Dose Cisplatin On Non-Small Cell Lung Cancer (NSCLC) Stem Cells
by: Nazilah, Abdul Satar
Published: (2018)

The Chemo-Sensitisation Effect Of Curcumin Against Low Dose Cisplatin On Non-Small Cell Lung Cancer (Nsclc) Stem Cells
by: Satar, Nazilah Abdul
Published: (2018)

Assessing narrative competence in preschool children: Key measures and ensuring reliability and validity
by: Wu, Bo, et al.
Published: (2025)

The effects of cisplatin on developing nociceptive pathways
by: Lloyd, Joseph
Published: (2017)

Using lean practices to improve current carbon labelling schemes for construction materials- a general framework
by: Wu, Peng, et al.
Published: (2012)

Dealing with lung cancer complications: how aggressive can we be?
by: How, Soon Hin
Published: (2013)

A review of benchmarking in carbon labelling schemes for building materials
by: Wu, Peng, et al.
Published: (2014)

Metal-based antitumor compounds: beyond cisplatin
by: Simpson, Peter, et al.
Published: (2019)

Unit ensures no overlaps
by: New Straits Times,
Published: (2008)

Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity
by: Kodama, A., et al.
Published: (2014)

The role of platelet-derived ADP and ATP in promoting pancreatic cancer cell survival and gemcitabine resistance
by: Elaskalani, Omar, et al.
Published: (2017)

Study On The Involvement Of Wif-1 In Oral Carcinogenesis Via Egfr And Wnt Signaling Pathways
by: Chow , Tan Wei
Published: (2015)

Upregulation and hypomethylation of EGFR in Formalin-fixed Paraffin Embedded FFPE tissues of colon adenocarcinoma
by: Othman, Rosfayati, et al.
Published: (2021)

Impact of Gemcitabine Chemotherapy and 3-Dimensional Conformal Radiation Therapy/5-Fluorouracil on Quality of life of patients Managed for Pancreatic Cancer
by: Short, Michelle, et al.
Published: (2013)

Achieving transparency in carbon labelling for construction materials – lessons from current assessment standards and carbon labels
by: Wu, Peng, et al.
Published: (2014)